DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).

[1]  S. Raimondi,et al.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients , 2014, Haematologica.

[2]  A. Lennartsson,et al.  Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR , 2013, BMC Cancer.

[3]  D. Markovitz,et al.  Concise Review: Role of DEK in Stem/Progenitor Cell Biology , 2013, Stem cells.

[4]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[5]  Elisa Ferrando-May,et al.  Intercellular trafficking of the nuclear oncoprotein DEK , 2013, Proceedings of the National Academy of Sciences.

[6]  N. Nassar,et al.  Stacking the DEK: From chromatin topology to cancer stem cells , 2013, Cell cycle.

[7]  Lina A. Thoren,et al.  HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis , 2012, Nucleic Acids Res..

[8]  D. Markovitz,et al.  DEK expression in Merkel cell carcinoma and small cell carcinoma , 2012, Journal of cutaneous pathology.

[9]  D. Markovitz,et al.  DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. , 2012, Stem cells and development.

[10]  James T. Webber,et al.  C/EBPα and DEK coordinately regulate myeloid differentiation. , 2012, Blood.

[11]  D. Markovitz,et al.  DEK expression in melanocytic lesions. , 2011, Human pathology.

[12]  D. Markovitz,et al.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. , 2011, Arthritis and rheumatism.

[13]  R. Henschler,et al.  The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation , 2010, Leukemia.

[14]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[15]  M. Soengas,et al.  Control of Tumorigenesis and Chemoresistance by the DEK Oncogene , 2010, Clinical Cancer Research.

[16]  S. Shurtleff,et al.  Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Chinnaiyan,et al.  Melanoma proliferation and chemoresistance controlled by the DEK oncogene. , 2009, Cancer research.

[18]  R. Hills,et al.  The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial , 2009, British journal of haematology.

[19]  G. Grosveld,et al.  Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. , 2009, Cancer research.

[20]  U. Gullberg,et al.  Identification of a novel and myeloid specific role of the leukemia‐associated fusion protein DEK‐NUP214 leading to increased protein synthesis , 2008, Genes, chromosomes & cancer.

[21]  D. Markovitz,et al.  The DEK Nuclear Autoantigen Is a Secreted Chemotactic Factor , 2006, Molecular and Cellular Biology.

[22]  F. Lottspeich,et al.  Hypophosphorylation of the architectural chromatin protein DEK in death‐receptor‐induced apoptosis revealed by the isotope coded protein label proteomic platform , 2006, Proteomics.

[23]  H. Matsuo,et al.  Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions , 2006, Molecular and Cellular Biology.

[24]  K. Münger,et al.  The Human DEK Proto-Oncogene Is a Senescence Inhibitor and an Upregulated Target of High-Risk Human Papillomavirus E7 , 2005, Journal of Virology.

[25]  H. Matsuo,et al.  The SAF-box domain of chromatin protein DEK , 2005, Nucleic acids research.

[26]  R. Knippers,et al.  The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin. , 2004, Gene.

[27]  I. Scholten,et al.  Functional Domains of the Ubiquitous Chromatin Protein DEK , 2004, Molecular and Cellular Biology.

[28]  B. Nagy,et al.  Real-Time PCR analysis of af4 and dek genes expression in acute promyelocytic leukemia t (15;17)patients , 2004, Experimental & Molecular Medicine.

[29]  S. Casas,et al.  Aberrant Expression of HOXA9, DEK, CBL and CSF1R in Acute Myeloid Leukemia , 2003, Leukemia & lymphoma.

[30]  F. O. Fackelmayer,et al.  Subcellular Localization of the Human Proto-oncogene Protein DEK* , 2001, The Journal of Biological Chemistry.

[31]  G. Grosveld,et al.  Overexpression of the Nucleoporin CAN/NUP214 Induces Growth Arrest, Nucleocytoplasmic Transport Defects, and Apoptosis , 1998, Molecular and Cellular Biology.

[32]  A. Hagemeijer,et al.  Dek-can rearrangement in translocation (6;9)(p23;q34). , 1992, Leukemia.

[33]  M. Vihinen,et al.  Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. , 2002, Haematologica.

[34]  M. Vihinen,et al.  Overexpression of translocation-associated fusion genes of FGFR 1 , MYC , NPM 1 , and DEK , but absence of the translocations in acute myeloid leukemia . A microarray analysis , 2002 .